sarfaraz k. niazi, ph.d., si, frsb, fpams, facb

Founding Executive Chairman and CSO, Sarfaraz is a widely recognized pioneer of biosimilars with track record of taking  biosimilars to US and other global markets. As an entrepreneur, he has raised hundreds of millions of dollars. He is also the founder of Therapeutic Proteins Inc (now Adello Biologics) that he left end of 2017. He is a prolific author, patent law practitioner and inventor with over 100 inventions. At KBL, Dr. Niazi is creating a novel and creative model that will assure fast-to-market biosimilars that will be affordable globally. More details.


sigrun hallmayer, md

Chief of Clinical Operations. Sigrun is a well-recognized oncologist, holding the Chair, Cancer Committee Advocate Lutheran General Hospital, Medical Director, ALGH Survivorship Program and Director, Oncology Specialists Research Institute OSRI in Park Ridge, IL. Sigrun has lead many clinical trials biosimilars prospective, phase I-III studies for  monoclonal antibodies, cytokines, and other treatment modalities. She has published widely and is highly recognized for her contributions to clinical trials management.   At KBL, Sigrun provides supervision of the clinical programs.

kbl - 1.jpg

brittany ristucci, mba

Director, Business Development. Brittany has over 15 years of experience in leadership and business coordination at leading healthcare systems including The Ohio State University, Northshore University Health System and the University of Chicago. She has helped built several startups through her consulting company VisAttain. At KBL, Brittany manages all business development needs including identifying and nurturing technical and business partnerships worldwide. She is also coordinating all financial and corporate compliance activities of KBL. 




Seven well-know experts coming aboard soon